When you hear the word Super-Recognizer, you may think of comic-book-hero-esque agents searching the underground to find people who went missing decades ago. Compared to this fantasy, the reality seems somewhat less exciting. Super-Recognizers (SRs) were initially reported a decade ago as a collateral while developing tests for developmental prosopagnosia. Today, the topic of SRs sparks interest from groups seeking to enhance scientific knowledge, public safety, or their monetary gain. With no immediate consequences of erroneous SR identification, there has been no pressure to establish a clear SR definition. This promotes heterogenous empirical evidence and the proliferation of unsupported claims in the media. Not only is this status quo unfortunate, it stands in opposition to the potential of special populations - both for science and application. SRs are a special population with imminent real-world value that can advance our understanding of brain functioning. To exploit their potential, I propose a needed formal framework for SR diagnosis, and introduce 70 cases identified based hereupon. These cases represent the core of a growing SR cohort, studied in my lab in the course of a long-term, multi-methodological research agenda involving academic and government collaborators. Finally, I provide recommendations for those interested in SR work, and highlight current caveats and future challenges.This commentary will summarise opinions on the progression of the next pillar of patient treatment; cell and gene therapy. The development of exemplar products will be discussed along with their respective journeys. This will be in comparison to present-day developments and the direction in which the field is heading with respect to future products. Important topics for consideration will be the use of various technologies, automation, scalability and the key considerations for those already involved, or those striving to enter the field. Discussions will consider the current Chemistry, manufacturing and control (CMC) procedures and where these will require consideration for improvement as we proceed into the future.Capping is a mechanical defect in tablets, which is attributed to multiple factors including intrinsic material properties and tableting conditions. A suitable non-destructive approach using acoustically derived elastic modulus has showed distinctive features between a defective tablet and a defect-free tablet. In this work, a semi-empirical model was developed to estimate flaw size in an internally defective tablet from the relationship among elastic modulus, tablet density, and time of flight (acoustic wave to traverse through the tablet). The model was found fundamentally consistent where the derived flaw size showed clear dependence on powder mechanical properties of seven diverse formulations studied. Furthermore, the flaw size was reasonably correlated with the internal tablet microstructure illustrated by X-ray micro-tomography findings, both qualitatively and quantitatively. This model could thus be efficiently implemented for risk-based evaluation of internal defects in visibly intact tablets to ensure robustness of drug products.Polymeric membranes have been used in several applications, including their use as curatives in cutaneous wounds. Bromelain has long been used for anti-inflammatory purposes, so the objective of this work was to produce carboxymethylcellulose-acetylated blends, incorporate bromelain, characterize the systems, compare the blends with bromelain loaded in nanoparticles and liposomes and, finally, to evaluate their healing potential. Four membrane formulations were produced by solvent evaporation the control, membranes containing free bromelain, bromelain-loaded nanoparticles (NPs) and bromelain-loaded liposomes (LIPs). The enzyme concentration was the same for all formulations. Transparent, flexible and intact films were obtained. The membranes containing free bromelain, bromelain-loaded NPs and bromelain-loaded LIPs had higher water content, lower water vapor permeability and maximum tensile strength, and greater elongation at rupture. The capacity to absorb simulated exudate was higher in samples containing free bromelain, and bioadhesion was reduced in the presence of free bromelain compared to the control. An in vivo assay was performed to verify the membranes' healing potential. Histological analysis revealed no edema on the 14th day in animals treated with membranes containing bromelain-loaded NPs and LIPs.The prevalence of age-related macular degeneration (AMD) has increased in the last years. Although anti-VEGF agents have improved the prognosis of exudative AMD, dry AMD has still devastating effects on elderly people vision. Oxidative stress and inflammation are mechanisms involved in AMD pathogenesis and its progression. Molecular pathways involving epidermal growth factor receptor (EGFR), bone morphogenetic protein (BMP4) and the nuclear erythroid related factor 2 (Nrf2) are behind oxidative stress in AMD due to their participation in antioxidant cellular pathways. https://www.selleckchem.com/pharmacological_epigenetics.html As a consequence of the disbalance produced in the antioxidant mechanisms, there is an activation of innate and adaptative immune response with cell recruitment, changes in complement factors expression, and modification of cellular milieu. Different therapies are being studied to treat dry AMD based on the possible effects on antioxidant molecular pathways or their action on the immune response. There is a wide range of treatments presented in this review, from natural antioxidant compounds to cell and gene therapy, based on their mechanisms. Finally, we hypothesize that alpha-1-antitrypsin (AAT), an anti-inflammatory and immunomodulatory molecule that can also modulate antioxidant cellular defenses, could be a good candidate for testing in AMD. This article is part of the special ssue on 'The Quest for Disease-Modifying Therapies for Neurodegenerative Disorders'.IgA exerts its primary function at mucosal surfaces, where it binds microbial antigens to regulate bacterial growth and epithelial attachment. One third of individuals with IgA deficiency (IgAD) suffers from recurrent mucosal infections, possibly related to an altered microbiota. We aimed to delineate the impact of IgAD and the IgA-autoantibody status on the composition and functional capacity of the gut microbiota.
We performed a paired, lifestyle-balanced analysis of the effect of IgA on the gut microbiota composition and functionality based on fecal samples from individuals with IgAD and IgA-sufficient household members (n= 100), involving quantitative shotgun metagenomics, species-centric functional annotation of gut bacteria, and strain-level analyses. We supplemented the data set with 32 individuals with IgAD and examined the influence of IgA-autoantibody status on the composition and functionality of the gut microbiota.
The gut microbiota of individuals with IgAD exhibited decreased richness and diversity and was enriched for bacterial species encoding pathogen-related functions including multidrug and antimicrobial peptide resistance, virulence factors, and type III and VI secretion systems.